[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholestasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholestasis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100657955","phase-2-nemolizumab-for-the-treatment-of-moderate-to-severe-chronic-hepatic-pruritus-100657955",false,"NCT07843420","Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus","Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: An Open-Label, Single-Arm, Exploratory Study","Inclusion Criteria:\n\n* Cholestatic pruritus secondary primary biliary sclerosis (PBS) or primary sclerosing cholangitis (PSC)\n* Pruritus that is chronic in duration (greater equal to 6 months)\n* Pruritus severity with a peak pruritus numerical rating score of ≥ 5 (moderate severity)\n* Model for End-Stage Liver Disease (MELD) score \\\u003C 15. This will capture patients with chronic stable liver disease without significant comorbid conditions and\u002For signs of rapidly progressive or decompensated liver failure\n* Willingness and ability to comply with scheduled clinic visits, physical exams, laboratory tests, questionnaires, effective contraception use, and other trial procedures\n\nExclusion Criteria:\n\n* Pruritus due to a primary inflammatory skin dermatosis or other forms of psychogenic pruritus utilizing skin biopsies to exclude as needed\n* Pregnant females. Urine pregnancy test required at screening\n* History of intrahepatic cholestasis of pregnancy\n* Any form of chronic hepatic pruritus associated with underlying malignancy\n* Liver transplant recipients\n* Drug-induced liver pruritus\n* ALT or AST greater than 3 times the upper limit of normal or total bilirubin greater than 2 times upper normal limit\n* Advanced liver disease indicators including, ascites requiring therapeutic paracentesis, history of spontaneous bacterial peritonitis, any grade of hepatic encephalopathy, or a documented history of variceal bleeding within the preceding six months\n* Severe coagulopathy with INR \\> 15\n* Any form of acute cholestatic liver disease\n* Allergy to nemolizumab or its ingredients\n* Inability to provide informed consent","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this research is to investigate the efficacy of nemolizumab in the treatment of adults with moderate to severe chronic hepatic pruritus.",[26,27,28,29,30],"Chronic Hepatic Pruritus","Cholestatic Liver Disease","Primary Biliary Cholangitis","Cholestasis","Primary Sclerosing Cholangitis","NOT_YET_RECRUITING","2026-09-21",{"date":34,"type":35},"2026-09-28","ACTUAL",{"date":37,"type":20},"2026-11",{"date":39,"type":20},"2028-11",{"name":41,"class":42},"Mayo Clinic","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100611978","congenital-heart-diseases-and-developmental-assessment-in-cholestatic-infants-under-two-years-100611978","NCT07247604","Congenital Heart Diseases and Developmental Assessment in Cholestatic Infants Under Two Years","Pattern of Congenital Heart Diseases and Developmental Evaluation in Children Below Two Years With Cholestasis at Assiut University Children's Hospital","Inclusion Criteria:\n\n* Children below 2 years presenting with cholestasis\n\nExclusion Criteria:\n\n* Prematurely born infants.","1 Month","2 Years",{"count":54,"type":20},106,"OBSERVATIONAL","Congenital heart diseases (CHDs) are common in infants with cholestasis due to shared prenatal and metabolic factors. This study aims to determine the frequency and types of CHDs and to assess physical and mental development in children below two years with cholestasis at Assiut University Children's Hospital.",[29,58],"Congenital Heart Disease","2025-11-22",{"date":61,"type":35},"2025-11-25",{"date":63,"type":20},"2025-12-11",{"date":65,"type":20},"2026-12-20",{"name":67,"class":42},"Assiut University"]